الفهرس 
chronic heart failureOnly 14 pages are availabe for public view
 |  | from | 102 |  |  |
| | | from | 102 | | |
Abstract
Background:
Alot of prospective studies focused on iron therapy in heart failure associated with iron defiency anemia. Although these trials studied the role of iron in heat failure. In this current study, the aim was to compare between I.V iron and oral iron therapy.
Methods:
-20 patients (group A) received 200 mg (10 ml) intravenous injections of iron sucrose R/(ferrosac) over 30 min into a peripheral vein diluted in 100cc glucose 5% and R/solucort if vial (hydrocortisone) and R/zantac ampule(H2 blocker) on day per day for 10 days and
-20 patients (group B) received oral iron 2:6 mg/kg R/(min-ravit or ferroteron) of body weight per day over 2 months.
- All patients in both groups were heart failure patients and Hb (8-11) g/dl, EF (25-50) %, TIBC > 460 who had been stable on standard heart failure medication.
- The local research and ethics committee gave study appro-val. Written, informed consent was obtained from all participants.
Evaluations:
Symptoms were assessed according to New York Heart Association (NYHA) functional classification.
Exercise capacity was quantified using a 6-min walk (6MW) test. Blood samples were taken for determination of hematologic variables, TIBC, and renal function before and after treatment.
Results:
There is statistically significant improvement in Hb in IV iron (group A) compared to oral iron (group B), p-value (0.023).
Also there is statistically significant improvement in NYHA class in IV iron (group A) compared to oral iron (group B), p value (0.004).
Also there is statistically significant improvement in 6MWT in IV iron (group A) compared to oral iron (group B), p-value (0.006).